ArticleInternational journal of clinical and experimental medicine2015
MiR-615 inhibited cell proliferation and cell cycle of human breast cancer cells by suppressing of AKT2 expression.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Quantitative Assessment of the Polymorphisms in the HOTAIR lncRNA and Cancer Risk: A Meta-Analysis of 8 Case-Control Studies.PloS one · 2016Pooled it
- Knockdown of LRP11-AS1 inhibits papillary thyroid tumor growth by modulating miR-615-3p/AKT2 axis.Translational oncology · 2025Article
- Regulatory Non-Coding RNAs during Porcine Viral Infections: Potential Targets for Antiviral Therapy.Viruses · 2024Review
- Expression of urinary exosomal miRNA-615-3p and miRNA-3147 in diabetic kidney disease and their association with inflammation and fibrosis.Renal failure · 2023Article
- Targeting HSF1 for cancer treatment: mechanisms and inhibitor development.Theranostics · 2023Review
- Vav1 Selectively Down-Regulates Akt2 through miR-29b in Certain Breast Tumors with Triple Negative Phenotype.Journal of personalized medicine · 2022Article
- Hydroxyacid Oxidase 2 (HAO2) Inhibits the Tumorigenicity of Hepatocellular Carcinoma and Is Negatively Regulated by miR-615-5p.Journal of immunology research · 2022Article
- miR-615 facilitates porcine epidemic diarrhea virus replication by targetingFrontiers in microbiology · 2022Article
- Akt Isoforms: A Family Affair in Breast Cancer.Cancers · 2021Review
- The Influence of rs1859168 Polymorphism on Serum Expression of HOTTIP and Its Target miR-615-3p in Egyptian Patients with Breast Cancer.Biomolecules · 2021Article
- MicroRNA-615-5p regulates the proliferation and apoptosis of breast cancer cells by targeting HSF1.Experimental and therapeutic medicine · 2021Article
- MicroRNA-615 functions as a tumor suppressor in osteosarcoma through the suppression of HK2.Oncology letters · 2020Article
- AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma.Respiratory research · 2020Article
- Exploration of Long Non-coding RNAs and Circular RNAs in Porcine Milk Exosomes.Frontiers in genetics · 2020Article
- Combined identification of three miRNAs in serum as effective diagnostic biomarkers for HNSCC.EBioMedicine · 2019Article
- Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma.Cancer medicine · 2019Article
- miR-615 Inhibits Prostate Cancer Cell Proliferation and Invasion by Directly Targeting Cyclin D2.Oncology research · 2019Article
- MicroRNA 615-3p Inhibits the Tumor Growth and Metastasis of NSCLC via Inhibiting IGF2.Oncology research · 2019Article
- Article
- MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) have emerged as important regulators that potentially play critical roles in various biological processes. Previous studies have shown that miR-615 regulates proliferation and apoptosis in many types of cancers. The biological function of this microRNA in breast cancer remains largely unexplored. In the present study, we found that miR-615 expression was markedly downregulated in breast cancer tissues and breast cancer cells. The enforced expression of miR-615 was able to inhibite the proliferation and anchorage-independent growth of breast cancer cells, while miR-615-in showed the opposite effect. Bioinformatics analysis further revealed AKT2, a putative tumor promoter as a potential target of miR-615. Ectopic expression of miR-615 led to downregulation of AKT2 protein, which resulted in the upregulation of p27 and p21 and the downregulation of cyclin D1. In sum, these results suggest that miR-615 represents a potential anti-onco-miR and participates in breast cancer carcinogenesis by suppressing AKT2 expression.
Indexed as
Identifiers
26064277PMC4443111W2203908836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.